| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 1,614 | - | 20,558 | 19,570 |
| Research and development | 38,361 | - | 32,074 | 31,257 |
| General and administrative | 10,304 | - | 10,274 | 9,971 |
| Total operating expenses | 48,665 | - | 42,348 | 41,228 |
| (loss) income from operations | -47,051 | - | -21,790 | -21,658 |
| Interest and other income | 3,571 | - | 4,441 | 5,766 |
| Total other income | 3,571 | - | 4,441 | 5,766 |
| (loss) income before provision for income taxes | -43,480 | -42,925 | -17,349 | -15,892 |
| Provision for (benefit from) income taxes | 654 | 178 | - | -1,860 |
| Net (loss) income | -44,134 | -43,103 | -17,349 | -14,032 |
| Unrealized gain on marketable securities | 221 | -37 | 480 | 1,301 |
| Total other comprehensive income | 221 | -37 | 480 | 1,301 |
| Total comprehensive (loss) income | -43,913 | -43,140 | -16,869 | -12,731 |
| Net (loss) income per share, basic (in dollars per share) | -1.06 | -1.04 | -0.42 | -0.35 |
| Net (loss) income per share, diluted (in dollars per share) | -1.06 | -1.04 | -0.42 | -0.35 |
| Weighted-average common shares outstanding, basic (in shares) | 41,462,567 | 41,338,752 | 41,073,732 | 40,629,602 |
| Weighted-average common shares outstanding, diluted (in shares) | 41,462,567 | 41,338,752 | 41,073,732 | 40,629,602 |
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA)